[{"orgOrder":0,"company":"Asamedic","sponsor":"Bormioli Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Aspirin","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Asamedic","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Asamedic \/ Bormioli Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Asamedic \/ Bormioli Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Asamedic

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Asamedic and Bormioli partners for the commercialization of Coxor (acetylsalicylic acid), a medication designed for emergency treatment of suspected acute myocardial infarction.

                          Brand Name : Coxor

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 19, 2024

                          Lead Product(s) : Aspirin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Bormioli Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank